Go to Health Care Provider version
| Diagnosis | ALL AML all solid tumours | Study Status | Closed |
| Phase | I |
| Age | Child, Adult - (Up to 25 years) | Randomisation | NO |
| Line of treatment | Disease relapse or progression |
| Routes of Treatment Administration | Oral tablet or suspension (Venetoclax)
IV Chemotherapies |
| Last Posted Update | 2024-03-18 |
| ClinicalTrials.gov # | NCT03236857 |
International Sponsor
AbbViePrincipal Investigators for Canadian Sites
The Hospital for Sick Children – Dr. Daniel Morgenstern
CHU Ste-Justine- Dr. Henrique Bittencourt
Centres
Medical contact
Dr. Henrique Bittencourt
Dr. Monia Marzouki
Dr. Sebastien Perreault (neuro-onc)
Social worker/patient navigator contact
Marie-Claude Charrette
Clinical research contact
Marie Saint-Jacques
Study Description
Venetoclax is a medication, taken by mouth, which selectively binds and blocks a molecule called BCL-2, restoring the ability for natural cell death in cancer cells that have the BCL-2 marker. It is expected to slow or stop the growth of cancer cells.
The aim of this study is to evaluate the dose, safety, tolerability, antitumor activity and other characteristics of venetoclax given with or without chemotherapy.
Inclusion Criteria
- Participants must have cancer that has come back or is not responding to current therapy
- Age up to 25 years
- Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team.
